Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02021734
Other study ID # 13-00065 [JIRB]
Secondary ID 12217/12
Status Active, not recruiting
Phase
First received
Last updated
Start date November 19, 2012
Est. completion date December 2025

Study information

Verified date December 2023
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools.


Description:

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. These include high-throughput sequencing and genotyping along with the necessary bioinformatics analyses that will lead to the discovery of the causes of most inherited diseases in the region.The secondary objective will be to build a comprehensive catalogue of genetic variation in the Arab world. This will include all detected mutations, not only the subset that are causing disease (from primary objective), but also known trait-altering mutations as well as general diversity on the DNA level among human populations of this region. This catalogue can become a widely useful resource for many projects down the road, as it relies on anonymizing individual samples and instead displaying data in aggregate as the cohorts of collected samples grow over the years. The study will include all genetic disorders from all ethnic backgrounds but Mendelian disease for which a gene mutation has already been identified will be excluded. Evidence of Mendelian Transmission determined by fulfilling one of the following criteria: Multiple affected family members (at least first degree relative with disease) History of consanguinity Severe disease in newborn in the absence of family history Sydromic disease in single individuals Congenital abnormality affecting major organ system(s) Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 400
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All included individuals must provide informed consent - All genetic disorders are included - All ethnic backgrounds are accepted - Disease must be genetic with no evident environmental cause - Evidence of Mendelian Transmission determined by fulfilling one of the following criteria: - Multiple affected family members (at least first degree relative with disease) - History of consanguinity - Severe disease in newborn in the absence of family history - Sydromic disease in single individuals - Congenital abnormality affecting major organ system(s) - Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension) Exclusion Criteria: - Individuals who do no consent to be included - Mendelian disease for which a gene mutation has already been identified - Individuals for which a molecular diagnosis has already been established by alternative method - Disease for which an environmental factor is most likely the cause - Disease for which late age of onset rule out Mendelian transmission - Common diseases for which late age of onset rule out Mendelian transmission

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Qatar Hamad Medical Corporation Doha

Sponsors (3)

Lead Sponsor Collaborator
Weill Medical College of Cornell University Hamad Medical Corporation, Weill Cornell Medical College in Qatar

Country where clinical trial is conducted

Qatar, 

Outcome

Type Measure Description Time frame Safety issue
Primary Next generation sequencing Use next generation sequencing to detect novel disease causing mutations 1 hour
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03211039 - Perinatal Precision Medicine N/A
Recruiting NCT03589079 - Delineation of Novel Monogenic Disorders in the United Arab Emirates Population
Enrolling by invitation NCT05290701 - Evaluating Prenatal Exome Sequencing Study